Shengfa Su

808 total citations · 1 hit paper
33 papers, 588 citations indexed

About

Shengfa Su is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shengfa Su has authored 33 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Shengfa Su's work include Lung Cancer Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Lung Cancer Research Studies (10 papers). Shengfa Su is often cited by papers focused on Lung Cancer Diagnosis and Treatment (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Lung Cancer Research Studies (10 papers). Shengfa Su collaborates with scholars based in China. Shengfa Su's co-authors include Chong Zhao, Tai‐Xiang Lu, Weiwei Xiao, Fei Han, Xiaowu Deng, Xueming Sun, Chunyan Chen, Chengguang Lin, Shaomin Huang and Weiwei Ouyang and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Radiotherapy and Oncology.

In The Last Decade

Shengfa Su

26 papers receiving 585 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities

2013 433 citations Shengfa Su, Fei Han et al. Radiotherapy and Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shengfa Su China	7	358	251	247	216	88	33	588
Chengguang Lin China	8	394 1.1×	209 0.8×	197 0.8×	250 1.2×	95 1.1×	13	563
Xue-Song Sun China	13	378 1.1×	275 1.1×	190 0.8×	195 0.9×	85 1.0×	51	621
Xueming Sun China	4	371 1.0×	200 0.8×	151 0.6×	226 1.0×	66 0.8×	12	473
To Wai Leung China	9	357 1.0×	188 0.7×	182 0.7×	260 1.2×	59 0.7×	13	494
Chi‐Chung Tong China	13	286 0.8×	271 1.1×	136 0.6×	230 1.1×	55 0.6×	31	590
Chun-Yan Chen China	8	399 1.1×	196 0.8×	166 0.7×	270 1.3×	51 0.6×	8	507
David R. Trevarthen United States	9	376 1.1×	164 0.7×	204 0.8×	251 1.2×	27 0.3×	13	516
Wai Man Hung China	7	577 1.6×	255 1.0×	287 1.2×	361 1.7×	103 1.2×	9	750
Kwan-Yee Chan Taiwan	10	380 1.1×	214 0.9×	150 0.6×	293 1.4×	31 0.4×	16	529
Jin‐Jie Yan China	10	292 0.8×	191 0.8×	110 0.4×	173 0.8×	40 0.5×	15	375

Countries citing papers authored by Shengfa Su

Since Specialization

Citations

This map shows the geographic impact of Shengfa Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengfa Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengfa Su more than expected).

Fields of papers citing papers by Shengfa Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengfa Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengfa Su. The network helps show where Shengfa Su may publish in the future.

Co-authorship network of co-authors of Shengfa Su

This figure shows the co-authorship network connecting the top 25 collaborators of Shengfa Su. A scholar is included among the top collaborators of Shengfa Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengfa Su. Shengfa Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Xinyue, et al.. (2025). Crabs: Consuming Resource via Auto-generation for LLM-DoS Attack under Black-box Settings. 11128–11150. 2 indexed citations

Zhang, Jing, et al.. (2025). Low-dose radiation as a potential strategy for alleviating lung injury caused by radiotherapy combined with immunotherapy: A preclinical study. Radiotherapy and Oncology. 206. 110823–110823.

Wang, Gang, Shasha Zhao, Jing Zhang, et al.. (2025). Exploring mechanisms of radiation-induced myocardial fibrosis using HMGB1 neutralizing antibody. Journal of Molecular Histology. 56(4). 262–262.

Yang, Hong, Guojian Liao, Lili Zhao, et al.. (2025). Effectiveness and safety of pirfenidone for radiation-induced lung injury in non-small cell lung cancer: a retrospective pilot study. BMC Cancer. 25(1). 1415–1415.

Zhu, Yiying, Weiwei Ouyang, Shengfa Su, et al.. (2024). Cardiac substructure radiation dose study of conventional radiotherapy for stage N2-3 non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). e20071–e20071.

Chen, Xiaxia, Shengfa Su, Wengang Yang, et al.. (2024). Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer. Cancer Medicine. 13(17). e70221–e70221. 1 indexed citations

Zhao, Shasha, Jing Zhang, Yao Liu, et al.. (2024). PD-1 Inhibitor Aggravate Irradiation-Induced Myocardial Fibrosis by Regulating TGF-β1/Smads Signaling Pathway via GSDMD-Mediated Pyroptosis. Inflammation. 48(1). 181–198. 7 indexed citations

Li, Qingsong, Cheng Hu, Shengfa Su, et al.. (2023). Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy. Frontiers in Oncology. 13. 974735–974735. 2 indexed citations

Hu, Cheng, et al.. (2023). Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study. Cancer Medicine. 12(14). 14949–14959. 2 indexed citations

10.

Zhao, Shasha, Gang Wang, Shengfa Su, et al.. (2022). The Effect of PD-1 Inhibitor Combined with Irradiation on HMGB1-Associated Inflammatory Cytokines and Myocardial Injury. Journal of Inflammation Research. Volume 15. 6357–6371. 3 indexed citations

11.

Zhao, Xing, Shengfa Su, Jun Zhang, et al.. (2022). Recombinant human endostatin combined with radiotherapy promotes cardiomyocyte apoptosis in rats via TGFβ1/Smads/CTGF signaling pathway. BMC Cardiovascular Disorders. 22(1). 97–97. 4 indexed citations

12.

Ouyang, Weiwei, Wengang Yang, Shengfa Su, et al.. (2021). Genetic characteristics of a patient with multiple primary cancers: A case report. World Journal of Clinical Cases. 9(28). 8563–8570. 2 indexed citations

13.

Li, Qingsong, Wengang Yang, Zhu Ma, et al.. (2021). Prognostic Model to Predict Overall Survival for Metastatic Non-Small Cell Lung Cancer Patients Treated With Chemotherapy Combined With Concurrent Radiation Therapy to the Primary Tumor: Analysis From Two Prospective Studies. Frontiers in Oncology. 11. 625688–625688. 2 indexed citations

14.

Ma, Zhu, Bing Lü, Tao Li, et al.. (2015). A prospective, multicenter, phase II clinical study of three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small-cell lung cancer—PPRA-RTOG003. Zhonghua fangshe zhongliuxue zazhi. 24(4). 359–364. 1 indexed citations

15.

Su, Shengfa, Tao Li, Bing Lü, et al.. (2015). Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China. International Journal of Radiation Oncology*Biology*Physics. 93(4). 769–777. 33 indexed citations

16.

Ouyang, Weiwei, Shengfa Su, Zhu Ma, et al.. (2014). Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy. Radiation Oncology. 9(1). 147–147. 6 indexed citations

17.

Ouyang, Weiwei, Shengfa Su, Bing Lü, et al.. (2014). Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study. BMC Cancer. 14(1). 491–491. 13 indexed citations

18.

Su, Shengfa, Weiwei Ouyang, Zhu Ma, et al.. (2014). The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy. Radiation Oncology. 9(1). 290–290. 15 indexed citations

19.

Su, Shengfa, Weiwei Ouyang, Bing Lü, et al.. (2013). Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study. BMC Cancer. 13(1). 474–474. 16 indexed citations

20.

Xiao, Weiwei, Tai‐Xiang Lu, Chong Zhao, Fei Han, & Shengfa Su. (2010). Impact of intensity-modulated radiotherapy on the 6th edition of UICC/AJCC staging system in nasopharyngeal carcinoma. Zhonghua fangshe zhongliuxue zazhi. 19(3). 181–184. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact